J&J Medical Connect
SYMTUZA®

(darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

SYMTUZA® (darunavir/ cobicistat/ emtricitabine/ tenofovir alafenamide)
Medical Information

Use of SYMTUZA in Patients Co-Infected with Hepatitis B or C

Last Updated: 08/07/2026

SUMMARY

  • Patients coinfected with HIV-1 and hepatitis B or C were excluded from phase 2-3 studies with SYMTUZA.1

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 02 June 2025 and did not identify any relevant citations pertaining to this topic.

References

Show
1 Data on File. Summary of Clinical Safety Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination Tablet for the Treatment of HIV-1 Infection in Adults and Adolescents. Janssen Research & Development. EDMS-ERI-134922118; 2017.  

Would you like to clear and leave your conversation? Message history will be lost.